Overview

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

Status:
Completed
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Treatments:
Pembrolizumab